RT Journal Article
SR Electronic
T1 Baseline Tumour Size as a Prognostic Factor for Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1683
OP 1691
DO 10.21873/anticanres.14932
VO 41
IS 3
A1 NAOKI FUKUDA
A1 KAZUHISA TODA
A1 AKIHIRO OHMOTO
A1 XIAOFEI WANG
A1 NAOMI HAYASHI
A1 TETSUYA URASAKI
A1 YASUYOSHI SATO
A1 KENJI NAKANO
A1 MAKIKO ONO
A1 JUNICHI TOMOMATSU
A1 HIROKI MITANI
A1 SHUNJI TAKAHASHI
YR 2021
UL http://ar.iiarjournals.org/content/41/3/1683.abstract
AB Background/Aim: Lenvatinib is standard therapy for radioiodine-refractory differentiated thyroid cancer (RR-DTC), although the optimal timing for starting treatment is still controversial. The aim of this study was to evaluate the prognostic impact of baseline tumour size (BTS) in patients with RR-DTC treated with lenvatinib. Patients and Methods: Fifty-one RR-DTC patients who had at least one measurable lesion and treated with lenvatinib were retrospectively analysed. BTS was defined as the sum of the longest dimensions of all measurable target lesions. Results: Median progression-free survival (PFS) and overall survival (OS) in the larger BTS (≥42 mm) group were shorter than those in the smaller (<42 mm) group. This result was more significant in patients with fast-growing tumours. BTS was an independent prognostic factor for both PFS and OS. Conclusion: Starting lenvatinib at BTS <42 mm should be recommended to achieve good treatment outcomes in patients with RR-DTC.